Skip to content
Catalyst

(4S)-4-hydroxy-L-isoleucineWhat was measured

Measured, with no finding

183 endpoints

Show what was measuredHide what was measured
  • basal glycemia and basal insulinemia after 6-day subchronic dosing, and glucose tolerance on IVGTT (rats) and OGTT (dogs), in normal and non-insulin-dependent diabetic rats; glucose-induced insulin release from isolated islets

    decreases

    Not recorded as a finding: the paper never states the instrument the node requires

    In non-insulin-dependent diabetic (NIDD) rats, a single intravenous administration of 4-OH-Ile (50 mg/kg) partially restored glucose-induced insulin response without affecting glucose tolerance; a 6-day subchronic administration of 4-OH-Ile (50 mg/kg, daily) reduced basal hyperglycemia, decreased basal insulinemia, and slightly, but significantly, improved glucose tolerance.

    PMID 10516120 · one of two readings recorded this

  • basal hyperglycemia

    decreases

    a 6-day subchronic administration of 4-OH-Ile (50 mg/kg, daily) reduced basal hyperglycemia, decreased basal insulinemia, and slightly, but significantly, improved glucose tolerance

    PMID 10516120 · one of two readings recorded this

  • basal insulinemia

    decreases

    a 6-day subchronic administration of 4-OH-Ile (50 mg/kg, daily) reduced basal hyperglycemia, decreased basal insulinemia, and slightly, but significantly, improved glucose tolerance

    PMID 10516120 · one of two readings recorded this

  • glucose-induced insulin release

    increases

    In vitro, 4-OH-Ile (200 microM) potentiated glucose (16.7 mM)-induced insulin release from NIDD rat-isolated islets.

    PMID 10516120 · one of two readings recorded this

  • glucose-induced insulin response

    increases

    In non-insulin-dependent diabetic (NIDD) rats, a single intravenous administration of 4-OH-Ile (50 mg/kg) partially restored glucose-induced insulin response without affecting glucose tolerance

    PMID 10516120 · one of two readings recorded this

  • glucose tolerance by intravenous glucose tolerance test in normal and NIDD rats and oral glucose tolerance test in normal dogs; basal glycemia and insulinemia; glucose-induced insulin release from isolated NIDD rat islets

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    During IVGTT in normal rats or OGTT in normal dogs, 4-OH-Ile (18 mg/kg) improved glucose tolerance.

    PMID 10516120 · one of two readings recorded this

  • glucose tolerance

    increases

    During IVGTT in normal rats or OGTT in normal dogs, 4-OH-Ile (18 mg/kg) improved glucose tolerance.

    PMID 10516120 · one of two readings recorded this

  • glucose tolerance

    increases

    During IVGTT in normal rats or OGTT in normal dogs, 4-OH-Ile (18 mg/kg) improved glucose tolerance.

    PMID 10516120 · one of two readings recorded this

  • glucose tolerance

    increases

    a 6-day subchronic administration of 4-OH-Ile (50 mg/kg, daily) reduced basal hyperglycemia, decreased basal insulinemia, and slightly, but significantly, improved glucose tolerance

    PMID 10516120 · one of two readings recorded this

  • glucose tolerance

    no effect

    In non-insulin-dependent diabetic (NIDD) rats, a single intravenous administration of 4-OH-Ile (50 mg/kg) partially restored glucose-induced insulin response without affecting glucose tolerance

    PMID 10516120 · one of two readings recorded this

  • glucose tolerance

    no effect

    The lactonic form of 4-OH-Ile was ineffective in normal rats.

    PMID 10516120 · one of two readings recorded this

  • hepatic glucose production

    decreases

    Euglycemic hyperinsulinemic clamp experiments revealed that ID-1101 can improve insulin resistance through an increase of peripheral glucose utilization rate in sucrose-lipid-fed rats and by decreasing hepatic glucose production in Zucker fa/fa rats.

    PMID 15082420 · one of two readings recorded this

  • insulinemia after chronic treatment in type 2 diabetic rats and obese Zucker fa/fa rats

    decreases

    Not recorded as a finding: CAT:outcome/fasting-insulin requires a stated overnight fast; the abstract states none (instrument_not_stated)

    Finally, chronic ID-1101 treatment significantly reduced insulinemia in type 2 diabetic rats and reduced the progression of hyperinsulinemia in insulin-resistant obese Zucker fa/fa rats.

    PMID 15082420 · one of two readings recorded this

  • insulinemia after chronic treatment in type 2 diabetic rats and Zucker fa/fa rats

    decreases

    Not recorded as a finding: fasting-insulin requires an overnight fast of at least 8 hours; the abstract states no fast or assay

    Finally, chronic ID-1101 treatment significantly reduced insulinemia in type 2 diabetic rats and reduced the progression of hyperinsulinemia in insulin-resistant obese Zucker fa/fa rats.

    PMID 15082420 · one of two readings recorded this

  • insulinemia

    decreases

    Finally, chronic ID-1101 treatment significantly reduced insulinemia in type 2 diabetic rats and reduced the progression of hyperinsulinemia in insulin-resistant obese Zucker fa/fa rats.

    PMID 15082420 · one of two readings recorded this

  • peripheral glucose utilization rate

    increases

    Euglycemic hyperinsulinemic clamp experiments revealed that ID-1101 can improve insulin resistance through an increase of peripheral glucose utilization rate in sucrose-lipid-fed rats and by decreasing hepatic glucose production in Zucker fa/fa rats.

    PMID 15082420 · one of two readings recorded this

  • PI 3-kinase activity (liver)

    increases

    Moreover, we demonstrated that a single injection of ID-1101 activates the PI 3-kinase activity in liver and muscle from normal rats but also in muscle from diabetic rats.

    PMID 15082420 · one of two readings recorded this

  • PI 3-kinase activity (muscle)

    increases

    Moreover, we demonstrated that a single injection of ID-1101 activates the PI 3-kinase activity in liver and muscle from normal rats but also in muscle from diabetic rats.

    PMID 15082420 · one of two readings recorded this

  • PI 3-kinase activity (muscle)

    increases

    Moreover, we demonstrated that a single injection of ID-1101 activates the PI 3-kinase activity in liver and muscle from normal rats but also in muscle from diabetic rats.

    PMID 15082420 · one of two readings recorded this

  • progression of hyperinsulinemia

    decreases

    Finally, chronic ID-1101 treatment significantly reduced insulinemia in type 2 diabetic rats and reduced the progression of hyperinsulinemia in insulin-resistant obese Zucker fa/fa rats.

    PMID 15082420 · one of two readings recorded this

  • total cholesterol (TC)

    decreases, p = 0.02

    which significantly decreased the plasma triglyceride levels by 33% (P<0.002), total cholesterol (TC) by 22% (P<0.02), and free fatty acids by 14%, accompanied by an increase in HDL-C/TC ratio by 39% in the dyslipidemic hamster model

    PMID 16246556 · one of two readings recorded this

  • free fatty acids

    decreases

    which significantly decreased the plasma triglyceride levels by 33% (P<0.002), total cholesterol (TC) by 22% (P<0.02), and free fatty acids by 14%, accompanied by an increase in HDL-C/TC ratio by 39% in the dyslipidemic hamster model

    PMID 16246556 · one of two readings recorded this

  • HDL-C/TC ratio

    increases

    which significantly decreased the plasma triglyceride levels by 33% (P<0.002), total cholesterol (TC) by 22% (P<0.02), and free fatty acids by 14%, accompanied by an increase in HDL-C/TC ratio by 39% in the dyslipidemic hamster model

    PMID 16246556 · one of two readings recorded this

  • plasma triglyceride levels

    decreases, p = 0.002

    which significantly decreased the plasma triglyceride levels by 33% (P<0.002), total cholesterol (TC) by 22% (P<0.02), and free fatty acids by 14%, accompanied by an increase in HDL-C/TC ratio by 39% in the dyslipidemic hamster model

    PMID 16246556 · one of two readings recorded this

  • glucose

    decreases, p = 0.01

    Alanine transaminase was elevated slightly (18%), and all markers were restored to near control values after treatment with 4-hydroxyisoleucine at 50 mg/kg per day for 8 weeks, the effect being significant (p < 0.01) for all markers.

    PMID 18680121 · one of two readings recorded this

  • glucose

    no effect

    This prolonged exposure to 4-hydroxyisoleucine was well tolerated in control animals and did not alter levels of glucose or liver damage markers significantly.

    PMID 18680121 · one of two readings recorded this

  • glucose

    increases, p = 0.001

    In fructose-fed rats, levels of glucose and liver damage marker aspartate transaminase were markedly (84% and 93%, respectively) and significantly elevated compared with controls (p < 0.001 for both).

    PMID 18680121 · one of two readings recorded this

  • glucose

    no effect

    In diabetic rats, treatment with 4-hydroxyisoleucine did not affect glucose or liver damage markers, but did improve HDL-cholesterol levels (31% increase, p < 0.05).

    PMID 18680121 · one of two readings recorded this

  • alanine transaminase

    decreases, p = 0.01

    Alanine transaminase was elevated slightly (18%), and all markers were restored to near control values after treatment with 4-hydroxyisoleucine at 50 mg/kg per day for 8 weeks, the effect being significant (p < 0.01) for all markers.

    PMID 18680121 · one of two readings recorded this

  • alanine transaminase

    increases

    Alanine transaminase was elevated slightly (18%), and all markers were restored to near control values after treatment with 4-hydroxyisoleucine at 50 mg/kg per day for 8 weeks, the effect being significant (p < 0.01) for all markers.

    PMID 18680121 · one of two readings recorded this

  • aspartate transaminase

    decreases, p = 0.01

    Alanine transaminase was elevated slightly (18%), and all markers were restored to near control values after treatment with 4-hydroxyisoleucine at 50 mg/kg per day for 8 weeks, the effect being significant (p < 0.01) for all markers.

    PMID 18680121 · one of two readings recorded this

  • aspartate transaminase

    increases, p = 0.001

    In fructose-fed rats, levels of glucose and liver damage marker aspartate transaminase were markedly (84% and 93%, respectively) and significantly elevated compared with controls (p < 0.001 for both).

    PMID 18680121 · one of two readings recorded this

  • blood glucose and liver damage markers in streptozotocin-diabetic rats

    no effect

    Not recorded as a finding: glucose fasting state not stated (CAT:outcome/fasting-blood-glucose requires an overnight fast); 'liver damage markers' do not name AST or ALT

    In diabetic rats, treatment with 4-hydroxyisoleucine did not affect glucose or liver damage markers, but did improve HDL-cholesterol levels (31% increase, p < 0.05).

    PMID 18680121 · one of two readings recorded this

  • blood glucose, AST and ALT in fructose-fed rats

    Not recorded as a finding: the sentence says markers were 'restored to near control values', no direction word per analyte; fasting not stated for fasting-blood-glucose; ALT and AST not named in the same sentence as the treatment effect

    Alanine transaminase was elevated slightly (18%), and all markers were restored to near control values after treatment with 4-hydroxyisoleucine at 50 mg/kg per day for 8 weeks, the effect being significant (p < 0.01) for all markers.

    PMID 18680121 · one of two readings recorded this

  • glucose and liver damage markers in streptozotocin diabetic rats

    no effect

    Not recorded as a finding: 'did not affect' is stated, but fasting is not stated for fasting-blood-glucose, and the liver markers are not named, so aspartate-aminotransferase and alanine-aminotransferase cannot be mapped

    In diabetic rats, treatment with 4-hydroxyisoleucine did not affect glucose or liver damage markers, but did improve HDL-cholesterol levels (31% increase, p < 0.05).

    PMID 18680121 · one of two readings recorded this

  • HDL-cholesterol

    increases, p = 0.05

    In diabetic rats, treatment with 4-hydroxyisoleucine did not affect glucose or liver damage markers, but did improve HDL-cholesterol levels (31% increase, p < 0.05).

    PMID 18680121 · one of two readings recorded this

  • liver damage markers

    no effect

    This prolonged exposure to 4-hydroxyisoleucine was well tolerated in control animals and did not alter levels of glucose or liver damage markers significantly.

    PMID 18680121 · one of two readings recorded this

  • liver damage markers

    no effect

    In diabetic rats, treatment with 4-hydroxyisoleucine did not affect glucose or liver damage markers, but did improve HDL-cholesterol levels (31% increase, p < 0.05).

    PMID 18680121 · one of two readings recorded this

  • tolerability

    This prolonged exposure to 4-hydroxyisoleucine was well tolerated in control animals and did not alter levels of glucose or liver damage markers significantly.

    PMID 18680121 · one of two readings recorded this

  • triglycerides

    decreases, p = 0.05

    4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.

    PMID 20140804 · one of two readings recorded this

  • blood glucose and plasma insulin

    decreases

    Not recorded as a finding: fasting-blood-glucose and fasting-insulin require a stated fast; the abstract states none

    4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.

    PMID 20140804 · one of two readings recorded this

  • blood glucose, plasma insulin and triglycerides

    decreases

    Not recorded as a finding: CAT:outcome/fasting-blood-glucose, fasting-insulin and serum-triglycerides each require a stated fast; the abstract states none (instrument_not_stated)

    4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.

    PMID 20140804 · one of two readings recorded this

  • blood glucose

    decreases, p = 0.05

    4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.

    PMID 20140804 · one of two readings recorded this

  • low-density lipoprotein-cholesterol

    decreases, p = 0.05

    4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.

    PMID 20140804 · one of two readings recorded this

  • plasma high-density lipoprotein-cholesterol

    increases, p = 0.05

    4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.

    PMID 20140804 · one of two readings recorded this

  • plasma insulin

    decreases, p = 0.05

    4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.

    PMID 20140804 · one of two readings recorded this

  • plasma triglycerides

    decreases

    Not recorded as a finding: serum-triglycerides requires a sample after a stated fast; the abstract states none

    4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.

    PMID 20140804 · one of two readings recorded this

  • total cholesterol

    decreases, p = 0.05

    4-Hydroxyisoleucine, when given orally to these mice at 50 mg kg(-1) dose level, significantly (p < 0.05) declined their elevated blood glucose, plasma insulin, triglycerides, total cholesterol, low-density lipoprotein-cholesterol levels and raised their declined plasma high-density lipoprotein-cholesterol level.

    PMID 20140804 · one of two readings recorded this

  • insulin level

    decreases

    Here we describe for the first time the anti-diabetic activity of 4HO-Ile in a model of type I diabetes, streptozotocin-treated rats, where levels of insulin are much reduced, by 65%, compared to normal animals.

    PMID 22397995 · one of two readings recorded this

  • lipids (cholesterol, HDL, LDL, triglycerides) and uric acid

    modulates

    Moreover the high levels of lipids (cholesterol, HDL, LDL and triglycerides) and uric acid in the diabetic rats, could be restored to levels found in non-diabetic controls by the treatment with 4HO-Ile.

    PMID 22397995 · one of two readings recorded this

  • plasma glucose, and plasma cholesterol, HDL, LDL, triglycerides and uric acid, in streptozotocin-induced type I diabetic rats

    decreases

    Not recorded as a finding: the paper never states the instrument the node requires

    Treatment of diabetic rats with daily doses of 4HO-Ile at 50 mg/kg/day for four weeks could reduce plasma glucose in the diabetic group.

    PMID 22397995 · one of two readings recorded this

  • plasma glucose in streptozotocin-induced type I diabetic rats; plasma cholesterol, HDL, LDL, triglycerides and uric acid

    decreases

    Not recorded as a finding: the paper never states the instrument the node requires

    Treatment of diabetic rats with daily doses of 4HO-Ile at 50 mg/kg/day for four weeks could reduce plasma glucose in the diabetic group.

    PMID 22397995 · one of two readings recorded this

  • plasma glucose

    decreases

    Treatment of diabetic rats with daily doses of 4HO-Ile at 50 mg/kg/day for four weeks could reduce plasma glucose in the diabetic group.

    PMID 22397995 · one of two readings recorded this

  • AMPK and Akt expression and phosphorylation

    increases

    Interestingly, it also increased the AMPK and Akt expression along with their phosphorylated forms in the liver and muscle tissues of treated animals.

    PMID 25454462 · one of two readings recorded this

  • blood lipid profile, glucose tolerance and insulin sensitivity in high-fructose-diet streptozotocin diabetic rats; glucose uptake and mitochondrial-biogenesis gene expression in L6 myotubes; AMPK and Akt expression and phosphorylation in liver and muscle

    Not recorded as a finding: this platform holds no node for the endpoint

    4-HIL (50 mg/kg) has improved blood lipid profile, glucose tolerance and insulin sensitivity in a diabetic rat model.

    PMID 25454462 · one of two readings recorded this

  • blood lipid profile, glucose tolerance and insulin sensitivity in high-fructose-diet streptozotocin diabetic rats; glucose uptake and mitochondrial biogenesis gene expression (PGC-1alpha, PGC-1beta, CPT 1, CPT 2) in L6 myotubes, liver and muscle; AMPK and Akt expression and phosphorylation

    Not recorded as a finding: the direction is carried only as a signed number

    4-HIL (50 mg/kg) has improved blood lipid profile, glucose tolerance and insulin sensitivity in a diabetic rat model.

    PMID 25454462 · one of two readings recorded this

  • blood lipid profile

    modulates

    4-HIL (50 mg/kg) has improved blood lipid profile, glucose tolerance and insulin sensitivity in a diabetic rat model.

    PMID 25454462 · one of two readings recorded this

  • glucose tolerance

    increases

    4-HIL (50 mg/kg) has improved blood lipid profile, glucose tolerance and insulin sensitivity in a diabetic rat model.

    PMID 25454462 · one of two readings recorded this

  • glucose uptake

    increases

    It has increased the glucose uptake in L6 myotubes in AMPK-dependent manner and upregulated the expression of genes (PGC-1α, PGC-1β, CPT 1 and CPT 2), which have role in mitochondrial biogenesis and energy metabolism in the liver, skeletal muscles as well as in L6 myotubes.

    PMID 25454462 · one of two readings recorded this

  • insulin sensitivity

    increases

    4-HIL (50 mg/kg) has improved blood lipid profile, glucose tolerance and insulin sensitivity in a diabetic rat model.

    PMID 25454462 · one of two readings recorded this

  • acetylcholine

    increases, p = 0.001

    Treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg considerably and dose-dependently raised the levels of GABA (one-way ANOVA: F(5,25) = 3.337, p < 0.001), acetylcholine (one-way ANOVA: F(5,25) = 0.3535, p < 0.001), and serotonin (one-way ANOVA: F(5,25) = 1.245, p < 0.001) in the brain homogenate of MeHg-treated rats.

    PMID 35745001 · one of two readings recorded this

  • nitrite

    decreases, p = 0.001

    Chronic treatment of three weeks with 4-HI at doses of 50 mg/kg and 100 mg/kg significantly lowered the levels of AchE(one-way ANOVA: F(5,25) = 2.460, p < 0.001), LDH (one-way ANOVA: F(5,25) = 4.095, p < 0.001), MDA (one-way ANOVA: F(5,25) = 1.081, p < 0.001), and nitrite (one-way ANOVA: F(5,25) = 2.286, p < 0.001).

    PMID 35745001 · one of two readings recorded this

  • serotonin

    increases, p = 0.001

    Treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg considerably and dose-dependently raised the levels of GABA (one-way ANOVA: F(5,25) = 3.337, p < 0.001), acetylcholine (one-way ANOVA: F(5,25) = 0.3535, p < 0.001), and serotonin (one-way ANOVA: F(5,25) = 1.245, p < 0.001) in the brain homogenate of MeHg-treated rats.

    PMID 35745001 · one of two readings recorded this

  • acetylcholinesterase (AchE)

    decreases, p = 0.001

    Chronic treatment of three weeks with 4-HI at doses of 50 mg/kg and 100 mg/kg significantly lowered the levels of AchE(one-way ANOVA: F(5,25) = 2.460, p < 0.001), LDH (one-way ANOVA: F(5,25) = 4.095, p < 0.001), MDA (one-way ANOVA: F(5,25) = 1.081, p < 0.001), and nitrite (one-way ANOVA: F(5,25) = 2.286, p < 0.001).

    PMID 35745001 · one of two readings recorded this

  • AchE, LDH, MDA and nitrite

    increases

    Long-term treatment withMeHg at a dose of 5 mg/kg for 21 dayson rats resulted in a considerable increase in AchE, LDH, MDA, and nitrite concentrations.

    PMID 35745001 · one of two readings recorded this

  • apoptotic markers

    modulates

    Furthermore,4-HI100 mg/kg treatment was more effective than 4-HI50 mg/kg treatment in restoring the abnormal levels of apoptotic markers in rats.

    PMID 35745001 · one of two readings recorded this

  • Bax (blood plasma)

    decreases, p = 0.001

    Likewise, continuous oral treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg remarkably decreased the level of the pro-apoptotic marker Bax in rat brain homogenate (one-way ANOVA: F(5,25) = 3.902, p < 0.001)and blood plasma (one-way ANOVA: F(5,25) = 1.642, p < 0.001)

    PMID 35745001 · one of two readings recorded this

  • Bax (brain homogenate)

    decreases, p = 0.001

    Likewise, continuous oral treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg remarkably decreased the level of the pro-apoptotic marker Bax in rat brain homogenate (one-way ANOVA: F(5,25) = 3.902, p < 0.001)and blood plasma (one-way ANOVA: F(5,25) = 1.642, p < 0.001)

    PMID 35745001 · one of two readings recorded this

  • Bcl-2 (blood plasma)

    increases, p = 0.001

    regular oral administration of 4-HI at doses of 50 mg/kg and 100 mg/kg for 21 days consecutively led to a considerable increase in the level of Bcl-2 protein in brain homogenate (one-way ANOVA: F(5,25) = 7.161, p < 0.001) and blood plasma (one-way ANOVA: F(5,25) = 0.9438, p < 0.001) in the MeHg-treated rats

    PMID 35745001 · one of two readings recorded this

  • Bcl-2 (brain homogenate)

    increases, p = 0.001

    regular oral administration of 4-HI at doses of 50 mg/kg and 100 mg/kg for 21 days consecutively led to a considerable increase in the level of Bcl-2 protein in brain homogenate (one-way ANOVA: F(5,25) = 7.161, p < 0.001) and blood plasma (one-way ANOVA: F(5,25) = 0.9438, p < 0.001) in the MeHg-treated rats

    PMID 35745001 · one of two readings recorded this

  • Bcl-2

    decreases

    In contrast, oral treatment with MeHg for 21 days led to a notable decline in anti-apoptotic Bcl-2 protein level in rat brain homogenate and blood plasma

    PMID 35745001 · one of two readings recorded this

  • body weight (days 1 and 7)

    no effect

    On days 1and 7, there was no significant difference between the groups.

    PMID 35745001 · one of two readings recorded this

  • body weight

    increases, p = 0.001

    Continuous oral administration of 4-HI50 mg/kg and 100 mg/kg significantly and dose-dependently improved the bodyweight when compared with MeHg-treated rats on the 14th, 21st, 28th, 35th and 42nd days of the experimental schedule (two-way ANOVA: F(30,180) = 187.8, p < 0.001)

    PMID 35745001 · one of two readings recorded this

  • body weight

    decreases

    On days 14, 21, 28, 35 and 42, a gradual decline in bodyweight was found in rats treated with MeHg compared to normal control, vehicle control, and 4-HI100 perse treated groups.

    PMID 35745001 · one of two readings recorded this

  • body weight

    increases

    On days 35 and 42, 4-HI100 mg/kg treated rats showed significant improvements in body weight restoration compared to the 4-HI50 mg/kg treatment rats.

    PMID 35745001 · one of two readings recorded this

  • brain section pathology (cortical tissue loss, white matter degeneration)

    decreases

    Persistent treatment with 4-HI50 mg/kg and 4-HI100 mg/kg remarkably reversed these morphological alterations in brain sections and restored demyelination, measured by demyelination volume and MBP level assessment.

    PMID 35745001 · one of two readings recorded this

  • brain section pathology (cortical tissue loss, white matter degeneration)

    decreases

    Among these, 4-HI100 mg/kg was more effective than 4-HI50 mg/kg in ameliorating the pathological abnormalities in brain sections.

    PMID 35745001 · one of two readings recorded this

  • caspase-3 and Bax

    increases

    Long-term oral MeHg administration significantly increased pro-apoptotic markers like caspase-3 and Bax in rat brain homogenate and blood plasma.

    PMID 35745001 · one of two readings recorded this

  • caspase-3 (blood plasma)

    decreases, p = 0.001

    Chronic oral administration of 4-HI at doses of 50 mg/kg and 100 mg/kg substantially reduced the level of caspase-3 in brain homogenate (one-way ANOVA: F(5,25) = 0.9588, p < 0.001) and blood plasma (one-way ANOVA: F(5,25) = 0.5116, p < 0.001)

    PMID 35745001 · one of two readings recorded this

  • caspase-3 (brain homogenate)

    decreases, p = 0.001

    Chronic oral administration of 4-HI at doses of 50 mg/kg and 100 mg/kg substantially reduced the level of caspase-3 in brain homogenate (one-way ANOVA: F(5,25) = 0.9588, p < 0.001) and blood plasma (one-way ANOVA: F(5,25) = 0.5116, p < 0.001)

    PMID 35745001 · one of two readings recorded this

  • cortical histopathology (oligodendrocytes, astrocytes)

    unclear

    With4-HI at a dose of 50 mg/kg, a gradual repair in the oligodendrocytes cells along with a slight decrease in the number of astrocytes was visible.

    PMID 35745001 · one of two readings recorded this

  • cortical histopathology (oligodendrocytes, microglia, necrosis)

    decreases

    The dose of4-HI 100 mg/kg restored the shape of oligodendrocyte cells and decreased the microglial and necrosis areas.

    PMID 35745001 · one of two readings recorded this

  • cortical histopathology (oligodendrocytes, microglia, necrosis)

    increases

    The methyl-mercury-treated group showed destruction of oligodendrocytes cells and the activation of microglia, and an increase in the area of necrosis.

    PMID 35745001 · one of two readings recorded this

  • demyelination (myelin content destruction)

    increases

    Long-term oral administration of the neurotoxin MeHg for 21 days substantially induced the destruction of the myelin content compared to normal control, vehicle control, and 4-HI100- perse-treated animals.

    PMID 35745001 · one of two readings recorded this

  • demyelination volume

    decreases, p = 0.001

    Treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg considerably reduced the demyelination volume relative to MeHg-treated rats (one-way ANOVA: F(5,25) = 1.627, p < 0.001).

    PMID 35745001 · one of two readings recorded this

  • demyelination volume

    decreases

    Consequently, 4-HI100 mg/kg showed a noticeable, dose-dependent improvement in myelin restoration compared to 4-HI50 mg/kg, as further evaluated by demyelination volume.

    PMID 35745001 · one of two readings recorded this

  • escape latency time (ELT)

    decreases, p = 0.001

    Chronic treatment with 4-HI 50 mg/kg and 100 mg/kg resulted in a significant decrease in ELT compared to the MeHg-treated group (two-way ANOVA: F(10,60) = 1.891, p < 0.001).

    PMID 35745001 · one of two readings recorded this

  • escape latency time (ELT)

    increases

    MeHg-treated rats showed a gradual increase in ELT compared to the normal control, vehicle control, and 4-HI100 perse groups.

    PMID 35745001 · one of two readings recorded this

  • escape latency time (ELT)

    decreases

    Administration of 4-HI100 mg/kg led to a marked decline in ELT compared to the 4-HI 50 mg/kg treatment

    PMID 35745001 · one of two readings recorded this

  • forelimb and hindlimb grip strength, grid force meter (Chatillon) in kgf

    increases, F(15,90) = 119.6

    Not recorded as a finding: CAT:outcome/handgrip-strength is hand-dynamometer grip in humans; rodent grid grip is a different instrument (endpoint_near_miss)

    Prolonged administration of 4-HI 50 mg/kg and 100 mg/kg showed a remarkable improvement in grip strength force on days 22, 32 and 42 when compared to MeHg-treated rats (two-way ANOVA: F(15,90) = 119.6, p < 0.001).

    PMID 35745001 · one of two readings recorded this

  • GABA, acetylcholine and serotonin

    decreases

    Oral administration of the toxin MeHg for 21 days consecutively resulted in a substantial decrease in GABA, acetylcholine, and serotonin levels.

    PMID 35745001 · one of two readings recorded this

  • GABA

    increases, p = 0.001

    Treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg considerably and dose-dependently raised the levels of GABA (one-way ANOVA: F(5,25) = 3.337, p < 0.001), acetylcholine (one-way ANOVA: F(5,25) = 0.3535, p < 0.001), and serotonin (one-way ANOVA: F(5,25) = 1.245, p < 0.001) in the brain homogenate of MeHg-treated rats.

    PMID 35745001 · one of two readings recorded this

  • GLP-1 concentration (brain homogenate)

    increases, p = 0.001

    Prolonged 4-HI50 mg/kg and 100 mg/kg treatment led to a significant and dose-dependent increase in the GLP-1 concentration in brain homogenate (one-way ANOVA: F (5,25) = 2.009, p < 0.001) and CSF (one-way ANOVA: F(5,25) = 2.021, p < 0.001), respectively.

    PMID 35745001 · one of two readings recorded this

  • GLP-1 concentration (CSF)

    increases, p = 0.001

    Prolonged 4-HI50 mg/kg and 100 mg/kg treatment led to a significant and dose-dependent increase in the GLP-1 concentration in brain homogenate (one-way ANOVA: F (5,25) = 2.009, p < 0.001) and CSF (one-way ANOVA: F(5,25) = 2.021, p < 0.001), respectively.

    PMID 35745001 · one of two readings recorded this

  • GLP-1 level

    decreases

    MeHg-induced rats illustrated a remarkable decrease in the level of GLP-1 as compared to the normal control, vehicle control, and 4-HI100 perse treated groups.

    PMID 35745001 · one of two readings recorded this

  • GLP-1 level

    increases

    Moreover, the 4-HI100 mg/kg dose was more efficient in restoring the level of GLP-1 in comparison with 4-HI50 mg/kg.

    PMID 35745001 · one of two readings recorded this

  • glutamate

    decreases, p = 0.001

    However, oral administration of 4-HI at doses of 50 mg/kg and 100 mg/kg lowered the concentration of glutamate (one-way ANOVA: F(5,25) = 1.372, p < 0.001) in rat brain homogenate in contrast to the MeHg-treated group.

    PMID 35745001 · one of two readings recorded this

  • glutamate

    increases

    In contrast, continuous oral MeHg intoxication led to a significant increase in the glutamate concentration in brain homogenate compared with normal control, vehicle control, and 4-HI100- perse-treated rats.

    PMID 35745001 · one of two readings recorded this

  • grip strength force

    increases, p = 0.001

    Prolonged administration of 4-HI 50 mg/kg and 100 mg/kg showed a remarkable improvement in grip strength force on days 22, 32 and 42 when compared to MeHg-treated rats (two-way ANOVA: F(15,90) = 119.6, p < 0.001)

    PMID 35745001 · one of two readings recorded this

  • grip strength force

    decreases

    The oral treatment with MeHg for 21 days consecutively led to a gradual decrease in grip strength force on days 22, 32 and 42 compared to normal control, vehicle control, and 4-HI100 perse groups.

    PMID 35745001 · one of two readings recorded this

  • grip strength force

    increases

    Among these, 4-HI100 mg/kg was more effective than 4-HI 50 mg/kg in the restoration of grip strength on days 32 and 42.

    PMID 35745001 · one of two readings recorded this

  • IGF-1 and GLP-1 in brain homogenate and CSF, ELISA

    increases

    Not recorded as a finding: CAT:outcome/serum-igf-1 requires serum; CAT:outcome/plasma-glp-1 requires postprandial plasma sampling; brain and CSF matrices differ (endpoint_near_miss)

    Chronic oral administration of 4-HI at the doses of 50 mg/kg and 100 mg/kg remarkably increased the IGF-1 level in brain homogenate (one-way ANOVA: F(5, 25) = 5.595, p < 0.001) and CSF samples (one-way ANOVA: F(5,25) = 0.971, p < 0.001).

    PMID 35745001 · both readings recorded this

  • IGF-1 level (brain homogenate)

    increases, p = 0.001

    Chronic oral administration of 4-HI at the doses of 50 mg/kg and 100 mg/kg remarkably increased the IGF-1 level in brain homogenate (one-way ANOVA: F(5, 25) = 5.595, p < 0.001) and CSF samples (one-way ANOVA: F(5,25) = 0.971, p < 0.001).

    PMID 35745001 · one of two readings recorded this

  • IGF-1 level (CSF)

    increases, p = 0.001

    Chronic oral administration of 4-HI at the doses of 50 mg/kg and 100 mg/kg remarkably increased the IGF-1 level in brain homogenate (one-way ANOVA: F(5, 25) = 5.595, p < 0.001) and CSF samples (one-way ANOVA: F(5,25) = 0.971, p < 0.001).

    PMID 35745001 · one of two readings recorded this

  • IGF-1 level

    decreases

    Oral administration of MeHg resulted in a significant decrease in the level of IGF-1 compared to the normal control, vehicle control, and 4-HI100 perse groups.

    PMID 35745001 · one of two readings recorded this

  • IGF-1 level

    increases

    Moreover, 4-HI100 mg/kg was more efficient than 4-HI50 mg/kg in restoring the IGF-1 protein level in rat brain homogenate and CSF samples.

    PMID 35745001 · one of two readings recorded this

  • IL-1β (blood plasma)

    decreases, p = 0.001

    Similarly, chronic oral treatment with 4-HI50 mg/kg and 4-HI100 mg/kg remarkably lowered the level of IL-1β in brain homogenate (one-way ANOVA: F(5,25) = 2.058, p < 0.001) and blood plasma (one-way ANOVA: F(5,25) = 1.370, p < 0.001) as opposed to the MeHg-toxin-administered rats.

    PMID 35745001 · one of two readings recorded this

  • IL-1β (brain homogenate)

    decreases, p = 0.001

    Similarly, chronic oral treatment with 4-HI50 mg/kg and 4-HI100 mg/kg remarkably lowered the level of IL-1β in brain homogenate (one-way ANOVA: F(5,25) = 2.058, p < 0.001) and blood plasma (one-way ANOVA: F(5,25) = 1.370, p < 0.001) as opposed to the MeHg-toxin-administered rats.

    PMID 35745001 · one of two readings recorded this

  • immobility time

    decreases, p = 0.001

    Long-term oral administration of 4-HI50 mg/kg and 4-HI100 mg/kg led to a considerable decline in the immobility time on days 28, 35 and 42 when compared to the MeHg-treated group (two-way ANOVA: F(15,90) = 87.32, p < 0.001)

    PMID 35745001 · one of two readings recorded this

  • immobility time

    increases

    The MeHg-treated group showed depressive-like behaviour and a gradual increase in immobility time compared to normal control, vehicle control, and 4-HI100 perse treated rats.

    PMID 35745001 · one of two readings recorded this

  • immobility time

    decreases

    Among these, 4-HI at a dose of 100 mg/kg was found to be more effective than 4-HI 50 mg/kg in reducing immobility time in rats on days 28, 35 and 42.

    PMID 35745001 · one of two readings recorded this

  • lactate dehydrogenase (LDH)

    decreases, p = 0.001

    Chronic treatment of three weeks with 4-HI at doses of 50 mg/kg and 100 mg/kg significantly lowered the levels of AchE(one-way ANOVA: F(5,25) = 2.460, p < 0.001), LDH (one-way ANOVA: F(5,25) = 4.095, p < 0.001), MDA (one-way ANOVA: F(5,25) = 1.081, p < 0.001), and nitrite (one-way ANOVA: F(5,25) = 2.286, p < 0.001).

    PMID 35745001 · one of two readings recorded this

  • locomotor activity and rearing

    decreases

    The MeHg-treated rats showed a progressive decline in the number of boxes crossed on days 11, 21, 31 and 41, and a considerable decrease in the number of rearings

    PMID 35745001 · one of two readings recorded this

  • locomotor activity and rearing

    increases

    On days 31 and 41, it was observed that 4-HI100 mg/kg considerably enhanced locomotion and improved the rearing scores when compared to the 4-HI 50 mg/kg treatment group

    PMID 35745001 · one of two readings recorded this

  • locomotor activity (boxes crossed)

    increases, p = 0.001

    Consequently, the regular administration of 4-HI 50 mg/kg and 100 mg/kg significantly enhanced the locomotor activity (two-way ANOVA: F(20,120) = 35.71, p < 0.001)

    PMID 35745001 · one of two readings recorded this

  • malondialdehyde (MDA)

    decreases, p = 0.001

    Chronic treatment of three weeks with 4-HI at doses of 50 mg/kg and 100 mg/kg significantly lowered the levels of AchE(one-way ANOVA: F(5,25) = 2.460, p < 0.001), LDH (one-way ANOVA: F(5,25) = 4.095, p < 0.001), MDA (one-way ANOVA: F(5,25) = 1.081, p < 0.001), and nitrite (one-way ANOVA: F(5,25) = 2.286, p < 0.001).

    PMID 35745001 · one of two readings recorded this

  • myelin basic protein (brain homogenate)

    increases, p = 0.001

    In comparison to the MeHg-treated group, long-term treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg enhanced MBP level in rat brain homogenate (one-way ANOVA: F(5,25) = 0.7205, p < 0.001) but lowered the MBP level in CSF (one-way ANOVA: F(5,25) = 0.5460, p < 0.001).

    PMID 35745001 · one of two readings recorded this

  • myelin basic protein (CSF)

    decreases, p = 0.001

    In comparison to the MeHg-treated group, long-term treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg enhanced MBP level in rat brain homogenate (one-way ANOVA: F(5,25) = 0.7205, p < 0.001) but lowered the MBP level in CSF (one-way ANOVA: F(5,25) = 0.5460, p < 0.001).

    PMID 35745001 · one of two readings recorded this

  • myelin basic protein (lower in brain, higher in CSF)

    modulates

    MBP levels were considerably lower in brain homogenate and higher in CSF samples in theMeHg-toxin-treated compared to the normal control, vehicle control, and 4-HI100 perse groups.

    PMID 35745001 · one of two readings recorded this

  • myelin basic protein restoration

    modulates

    It was also found that 4-HI100 mg/kg administration effectively restored the altered MBP levels compared to 4-HI50 mg/kg administration

    PMID 35745001 · one of two readings recorded this

  • neuroinflammatory cytokines (TNF-α, IL-1β)

    decreases

    Meanwhile, 4-HI100 mg/kg treatment showed a marked improvement in reducing the level of these neuroinflammatory cytokines compared to the 4-HI50 mg/kg dose.

    PMID 35745001 · one of two readings recorded this

  • neurotransmitter imbalance

    modulates

    Among these, the most significant improvements were observed in 4-HI100-mg/kg-treated rats versus the 4-HI50-mg/kg-treated rats in restoring neurotransmitter imbalance.

    PMID 35745001 · one of two readings recorded this

  • oxidative stress markers and antioxidants

    modulates

    Compared to 4-HI50 mg/kg, the 4-HI100 mg/kg treatment significantly reduced oxidative stress markers while restoring antioxidant levels in a dose-dependent manner.

    PMID 35745001 · one of two readings recorded this

  • rearing score (anxiety)

    increases, p = 0.001

    and restored the level of anxiety (rearing score)(two-way ANOVA: F(20,120) = 16.16, p < 0.001) as compared to MeHg-treated rats

    PMID 35745001 · one of two readings recorded this

  • reduced glutathione (GSH)

    increases, p = 0.001

    However, 4-HI50 mg/kg and 100 mg/kg remarkably restored the anti-oxidant defence system by considerably increasing the levels of reduced glutathione (one-way ANOVA: F(5,25) = 1.226, p < 0.001) and SOD (one-way ANOVA: F(5,25) = 0.8858, p < 0.001) when compared with MeHg-treated rats.

    PMID 35745001 · one of two readings recorded this

  • relative brain-body weight ratio

    no effect

    The normal and vehicle control groups showed no significant difference in the relative brain–body weight ratio compared to 4-HI perse treated rats.

    PMID 35745001 · one of two readings recorded this

  • relative brain-body weight ratio

    increases, p = 0.001

    Long-term oral administration of 4-HI at the doses of 50 mg/kg and 100 mg/kg substantially enhanced the relative brain–body weight ratio compared to the MeHg-treated rats (one-way ANOVA: F(5,25) = 0.632, p < 0.001)

    PMID 35745001 · one of two readings recorded this

  • relative brain-body weight ratio

    decreases

    Moreover, compared to the normal control, vehicle control, and 4-HI100 perse groups, MeHg-induced rats demonstrated a steady decline in relative brain–body weight ratio.

    PMID 35745001 · one of two readings recorded this

  • relative brain-body weight ratio

    increases

    Compared to the 4-HI 50 mg/kg treated group, 4-HI100 mg/kg demonstrated a considerable increase in relative brain–body weight ratio.

    PMID 35745001 · one of two readings recorded this

  • SOD and GSH

    decreases

    In contrast, oral MeHg administration led to a substantial decline in antioxidants like SOD and GSH compared to normal control, vehicle control, and 4-HI100- perse-treated groups.

    PMID 35745001 · one of two readings recorded this

  • superoxide dismutase (SOD)

    increases, p = 0.001

    However, 4-HI50 mg/kg and 100 mg/kg remarkably restored the anti-oxidant defence system by considerably increasing the levels of reduced glutathione (one-way ANOVA: F(5,25) = 1.226, p < 0.001) and SOD (one-way ANOVA: F(5,25) = 0.8858, p < 0.001) when compared with MeHg-treated rats.

    PMID 35745001 · one of two readings recorded this

  • time spent in target quadrant (TSTQ)

    increases, p = 0.001

    Long-term oral treatment with 4-HI 50 mg/kg and 100 mg/kg comparatively increased the TSTQ compared to theMeHg-treated group (one-way ANOVA: F(5,25) = 1.967, p < 0.001).

    PMID 35745001 · one of two readings recorded this

  • time spent in target quadrant (TSTQ)

    decreases

    MeHg-induced rats demonstrated a more substantial decrease in time spent in the target zone than in the normal control, vehicle control, and 4-HI100 perse groups.

    PMID 35745001 · one of two readings recorded this

  • time spent in target quadrant (TSTQ)

    increases

    Relatively, 4-HI100 mg/kg showed a significant rise in TSTQ compared to 4-HI-50 mg/kg-treated rats.

    PMID 35745001 · one of two readings recorded this

  • TNF-α (blood plasma)

    decreases, p = 0.001

    Treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg significantly lessened the TNF-α level in rat brain homogenate (one-way ANOVA: F(5,25) = 3.181, p < 0.001) and blood plasma (one-way ANOVA: F(5,25) = 1.682, p < 0.001), respectively.

    PMID 35745001 · one of two readings recorded this

  • TNF-α (brain homogenate)

    decreases, p = 0.001

    Treatment with 4-HI at doses of 50 mg/kg and 100 mg/kg significantly lessened the TNF-α level in rat brain homogenate (one-way ANOVA: F(5,25) = 3.181, p < 0.001) and blood plasma (one-way ANOVA: F(5,25) = 1.682, p < 0.001), respectively.

    PMID 35745001 · one of two readings recorded this

  • whole-brain morphology and brain weight

    increases

    Continuous oral administration of 4-HI at doses of 50 mg/kg and 100 mg/kg was observed to be efficient in restoring the alterations in brain weight and effectively reducing cortical degeneration.

    PMID 35745001 · one of two readings recorded this

  • whole-brain morphology and brain weight

    decreases

    MeHg-treated rat brains showed shrinkage in size and reduced overall brain mass compared to normal control, vehicle control, and 4-HI- perse-treated groups.

    PMID 35745001 · one of two readings recorded this

  • whole-brain morphology and brain weight

    increases

    However, 4-HI100-mg/kg-treated rats showed significant improvements in whole-brain morphology compared to the 4-HI50 mg/kg treated rats.

    PMID 35745001 · one of two readings recorded this

  • abnormal sperm morphology

    no effect

    However, sperm morphology in all three mice groups was less defective, with no significant differences.

    PMID 40917356 · one of two readings recorded this

  • blood glucose during insulin tolerance test (ITT)

    decreases

    In addition, the insulin tolerance test (ITT) revealed that unlike mice with obesity that were highly resistant to insulin injection, mice treated with 4-HIL had a significantly lower blood glucose concentration, similar to that in ND mice.

    PMID 40917356 · one of two readings recorded this

  • blood glucose during pyruvate tolerance test (PTT)

    unclear

    The pyruvate tolerance test (PTT) results showed a significant enhancement in blood glucose concentration in 4-HIL treated mice compared to that in mice with obesity.

    PMID 40917356 · one of two readings recorded this

  • body weight

    decreases

    Consistent with previous reports, we observed that 4-HIL treatment significantly reduced the body weight of mice in the HFD group compared to HFD mice without treatment.

    PMID 40917356 · one of two readings recorded this

  • days to pregnancy and pups per litter (mating trial)

    increases

    We noticed that 4-HIL treated mice were able to impregnate females in a shorter period and produced a significantly higher number of pups per litter than HFD group males.

    PMID 40917356 · one of two readings recorded this

  • differentially expressed genes (up/down) in testis

    modulates

    In addition, 281 genes were upregulated and 188 genes were downregulated in the testes of 4-HIL mice.

    PMID 40917356 · one of two readings recorded this

  • differentially expressed genes (up/down) in testis

    modulates

    Among these genes, 206 were upregulated and 282 were downregulated in the testes of the mice with obesity.

    PMID 40917356 · one of two readings recorded this

  • epididymal adipose tissue weight

    decreases

    Not recorded as a finding: CAT:outcome/fat-mass is whole-body adipose mass; a single fat-pad weight is a different construct (endpoint_near_miss)

    Lastly, we found reduced epididymal adipose weight in 4-HIL mice compared with that in mice with obesity.

    PMID 40917356 · one of two readings recorded this

  • epididymal adipose weight

    decreases

    Not recorded as a finding: no node; fat-mass is whole-body adipose mass

    Lastly, we found reduced epididymal adipose weight in 4-HIL mice compared with that in mice with obesity.

    PMID 40917356 · one of two readings recorded this

  • epididymal adipose weight

    decreases

    Lastly, we found reduced epididymal adipose weight in 4-HIL mice compared with that in mice with obesity.

    PMID 40917356 · one of two readings recorded this

  • epididymal sperm count and concentration, CASA (TOX IVOS)

    increases

    Not recorded as a finding: sperm-concentration requires ejaculate semen analysis per WHO methodology; this is epididymal sperm diluted in culture medium

    Based on the CASA results, 4-HIL treated mice had a significantly higher sperm count and concentration than those in the HFD group.

    PMID 40917356 · one of two readings recorded this

  • epididymal sperm count and concentration, computer-assisted sperm analysis (TOX IVOS)

    increases

    Not recorded as a finding: CAT:outcome/sperm-concentration requires ejaculate semen analysis per WHO methodology; this is epididymal sperm in mice (endpoint_near_miss)

    Based on the CASA results, 4-HIL treated mice had a significantly higher sperm count and concentration than those in the HFD group.

    PMID 40917356 · one of two readings recorded this

  • epididymal sperm count and concentration

    increases

    Based on the CASA results, 4-HIL treated mice had a significantly higher sperm count and concentration than those in the HFD group.

    PMID 40917356 · one of two readings recorded this

  • fasting blood glucose before treatment (HFD vs ND)

    increases

    Prior to treatment, HFD mice (mice with obesity) had a significantly higher blood glucose concentration than ND mice (Supplementary Figures S1B–D)

    PMID 40917356 · one of two readings recorded this

  • genes identified by testis mRNA sequencing

    A total of 25,702 genes were identified.

    PMID 40917356 · one of two readings recorded this

  • germinal epithelium congestion of seminiferous tubule lumen

    decreases

    however, 4-HIL treated mice had less crowded germinal epithelia, leading to visible boundaries in the lumen of the seminiferous tubules

    PMID 40917356 · one of two readings recorded this

  • glucose tolerance (GTT)

    increases

    After six weeks of treatment, mice with obesity treated with 4-HIL showed improved glucose tolerance compared to HFD mice.

    PMID 40917356 · one of two readings recorded this

  • glucose tolerance, intraperitoneal glucose tolerance test (2 g/kg), glucometer

    Not recorded as a finding: no node for an intraperitoneal GTT in mice; postprandial-glucose-auc requires an oral load or mixed drink

    After six weeks of treatment, mice with obesity treated with 4-HIL showed improved glucose tolerance compared to HFD mice.

    PMID 40917356 · one of two readings recorded this

  • IL-6 and TNFα concentration

    decreases

    In addition, inflammatory markers, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNFα), were assessed, and their serum and testis concentrations were found to be reduced in 4-HIL treated mice compared to those in HFD mice (Supplementary Figures S2C, D)

    PMID 40917356 · one of two readings recorded this

  • IVF 4-cell embryos (4-HIL vs normal diet)

    decreases

    However, the percentage of 4-cell embryos produced from the sperms of 4-HIL treated mice was significantly lower than that of 4-cell embryos from normal diet-fed mice.

    PMID 40917356 · one of two readings recorded this

  • IVF 4-cell embryos (HFD vs 4-HIL)

    increases

    In addition, there was a significantly reduced number of 4-cell embryos obtained from mice with obesity (HFD group) compared to that of 4-HIL treated mice.

    PMID 40917356 · one of two readings recorded this

  • IVF embryos progressing to blastocyst

    increases

    Approximately 30% of the embryos from mice in the HFD group progressed to the blastocyst stage, which was lower than the 55% and 61% of blastocysts derived from 4-HIL treated and normal control mice, respectively.

    PMID 40917356 · one of two readings recorded this

  • IVF zygote number (fertilization rate)

    no effect

    We observed that the fertilization rates among the mice groups were high, with no significant difference in the number of zygotes produced.

    PMID 40917356 · one of two readings recorded this

  • MDA concentration

    decreases

    We found a decrease and significant reduction of MDA concentration in the serum and testis respectively of 4-HIL-treated mice compared to those in the HFD group (Supplementary Figure S2A)

    PMID 40917356 · one of two readings recorded this

  • pups per litter and days to pregnancy in mating trials; IVF embryo development

    increases

    Not recorded as a finding: no node

    We noticed that 4-HIL treated mice were able to impregnate females in a shorter period and produced a significantly higher number of pups per litter than HFD group males.

    PMID 40917356 · one of two readings recorded this

  • serum and testis MDA and SOD, ELISA

    decreases

    Not recorded as a finding: malondialdehyde-circulating requires TBARS or HPLC, this was ELISA; serum decrease not stated as significant; SOD described only as 'optimized'

    We found a decrease and significant reduction of MDA concentration in the serum and testis respectively of 4-HIL-treated mice compared to those in the HFD group (Supplementary Figure S2A).

    PMID 40917356 · one of two readings recorded this

  • serum FSH, LH and testosterone direction

    unclear

    FSH levels were higher in 4-HIL-treated mice than in HFD mice, and LH levels within 4-HIL mice were similar to those of ND mice, and testosterone levels were lower in HFD mice than in 4-HIL-treated mice.

    PMID 40917356 · one of two readings recorded this

  • serum LDL-c, HDL-c and triglycerides, Nanjing Jiancheng kits

    Not recorded as a finding: the sentence says the lipids were 'remarkably optimized' with no direction per analyte and no fast stated; ldl-cholesterol, hdl-cholesterol and serum-triglycerides cannot take a direction from it

    However, after treatment, the same lipid parameters were found to be remarkably optimized in 4-HIL treated mice compared to those without treatment.

    PMID 40917356 · both readings recorded this

  • serum lipids before treatment (LDL-c, TG high; HDL-c low)

    modulates

    Furthermore, before the mice with obesity were treated with 4-HIL, they exhibited high serum concentrations of low-density lipoprotein cholesterol (LDL-c) and triglycerides (TG) and low serum concentrations of high-density lipoprotein cholesterol (HDL-c) (Supplementary Figure S1E)

    PMID 40917356 · one of two readings recorded this

  • serum lipids (LDL-c, TG, HDL-c)

    modulates

    However, after treatment, the same lipid parameters were found to be remarkably optimized in 4-HIL treated mice compared to those without treatment.

    PMID 40917356 · one of two readings recorded this

  • serum testosterone, FSH and LH, ELISA

    Not recorded as a finding: not significant and the sentence states no two-sided absence per hormone; total-testosterone cannot take a direction

    4-HIL treatment improved spermatogenic hormone levels, but no statistically significant differences were observed.

    PMID 40917356 · both readings recorded this

  • SOD level

    increases

    Similarly, in 4-HIL-treated mice, SOD levels were optimized, with a restoration of SOD concentration in the serum and testis (Supplementary Figure S2B)

    PMID 40917356 · one of two readings recorded this

  • spem1 and spata24 relative normalized expression (qPCR)

    increases

    The qPCR results revealed significantly higher relative normalized expression levels of spem1 and spata24 in the testes of mice treated with 4-HIL than in HFD group.

    PMID 40917356 · one of two readings recorded this

  • spermatogenesis genes dazl, insl6, spem1, spata24 (RNA-seq)

    increases

    with dazl, insl6, spem1, and spata24 upregulated in the testes of mice treated with 4-HIL and downregulated in the testes of mice with obesity (Supplementary Figure S3A)

    PMID 40917356 · one of two readings recorded this

  • spermatogenic hormones (FSH, LH, testosterone)

    no effect

    4-HIL treatment improved spermatogenic hormone levels, but no statistically significant differences were observed.

    PMID 40917356 · one of two readings recorded this

  • testicular apoptotic cells

    no effect

    Furthermore, in terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays, we observed a higher number of apoptotic cells in HFD group mice than in the 4-HIL treatment group; however, no statistically significant difference was established.

    PMID 40917356 · one of two readings recorded this

  • testicular lipid deposition

    decreases

    Additionally, Oil Red O staining revealed intense lipid deposition in the peritubular spaces and interstitium of the testes of HFD group mice, as opposed to the testes of 4-HIL treated mice.

    PMID 40917356 · one of two readings recorded this

  • testicular spem1 and spata24 mRNA expression, qPCR

    increases

    Not recorded as a finding: gene expression is not an outcome node or a protein-activity mechanism

    The qPCR results revealed significantly higher relative normalized expression levels of spem1 and spata24 in the testes of mice treated with 4-HIL than in HFD group.

    PMID 40917356 · both readings recorded this

  • testis weight

    no effect

    We first examined the testes of mice from all three (3) groups after 16 weeks of feeding and treatment and found no significant difference in testis weight among the groups.

    PMID 40917356 · one of two readings recorded this

  • IGF-1, GLP-1 and cytokine mRNA expression

    modulates

    Additionally, qRT-PCR showed that 4-HI administration modulated mRNA expression of IGF-1, GLP-1, and cytokines.

    PMID 41187648 · one of two readings recorded this

  • myelin repair, neuroinflammation, hematological profile and brain pathology

    modulates

    Histopathological analysis revealed enhanced myelin repair, reduced neuroinflammation, normalized hematological profiles, and mitigated pathological alterations in various brain regions.

    PMID 41187648 · one of two readings recorded this

  • neurobehavioral performance (neuromuscular coordination, locomotion, cognition), pro-inflammatory cytokines, apoptotic markers, neurotransmitter levels, hematological indices, histopathological myelin repair, and IGF-1/GLP-1 mRNA by qRT-PCR in ethidium-bromide-demyelinated rats

    Not recorded as a finding: this platform holds no node for the endpoint

    The study found that 4-HI treatment improved neuromuscular coordination, locomotion, and cognitive function.

    PMID 41187648 · one of two readings recorded this

  • neuromuscular coordination, locomotion and cognitive function

    increases

    The study found that 4-HI treatment improved neuromuscular coordination, locomotion, and cognitive function.

    PMID 41187648 · one of two readings recorded this

  • pro-inflammatory cytokines, pro-apoptotic markers and neurotransmitter imbalance

    decreases

    It reduced pro-inflammatory cytokines, pro-apoptotic markers, and restored neurotransmitter imbalances.

    PMID 41187648 · one of two readings recorded this